Latest Articles

Publication Date
All News Scientific
A severe ME/CFS patient in Pakistan is urgently fundraising for crucial surgery - The Canary

A severe ME/CFS patient in Pakistan is urgently fundraising for crucial surgery The Canary

Published: Dec. 10, 2024, 7:25 p.m.
Read Full Article
'A game changer': help on way for rural women with endo - Shepparton News

'A game changer': help on way for rural women with endo Shepparton News

Published: Dec. 10, 2024, 7 p.m.
Read Full Article
Early Recurrence After Surgery in FIGO 2023 Stage I-III Endometrial Cancer: Characteristics and risk factors - Frontiers

Early Recurrence After Surgery in FIGO 2023 Stage I-III Endometrial Cancer: Characteristics and risk factors Frontiers

Published: Dec. 10, 2024, 4:36 p.m.
Read Full Article
Endometriosis framework pushed back - Newstalk

Endometriosis framework pushed back Newstalk

Published: Dec. 10, 2024, 2:27 p.m.
Read Full Article
"What is Airbnb?": List of top 10 questions Kenyans asked Google in 2024 - Tuko.co.ke

"What is Airbnb?": List of top 10 questions Kenyans asked Google in 2024 Tuko.co.ke

Published: Dec. 10, 2024, 12:45 p.m.
Read Full Article
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - BioSpace

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer BioSpace

Published: Dec. 10, 2024, 12:23 p.m.
Read Full Article
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - Yahoo Finance

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer Yahoo Finance

Published: Dec. 10, 2024, 11 a.m.
Read Full Article
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PR Newswire

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer PR Newswire

Published: Dec. 10, 2024, 11 a.m.
Read Full Article
IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer - StockTitan

IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer StockTitan

Published: Dec. 10, 2024, 11 a.m.
Read Full Article
Women in the UK: share your experience of gynaecological pain - The Guardian

Women in the UK: share your experience of gynaecological pain The Guardian

Published: Dec. 10, 2024, 10:49 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!